Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Locally Advanced Solid Tumor 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × E7046 × Clear all
NCT04975958 2025-06-22

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Locally Advanced Solid Tumor

NCT03152370 2021-10-04

PRAER 1

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed
29 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡